Ahmedabad: Ahmedabad-based Cadila Healthcare (Zydus Cadila) today announced that the company has received the final approval from the US drugs regulator, US Food and Drug Administration (USFDA) to market a drug useful for treatment arthritis.
In a statement on Thursday, Cadila informed, “ The company has received final approval from the US drugs regulator US Food and Drug Administration (USFDA) to market Etodolac Extended-release Tablets USP, 400 mg, 500 mg, and 600 mg. The drug is prescribed for treatment of juvenile arthritis, rheumatoid arthritis and osteoarthritis.”
The group now has 88 approvals and has so far filed 216 ANDAs since the commencement of filing process in FY 2003-04, it added.
Cadila Healthcare shares ended almost flat on the stock exchanges on Thursday. The stock ended at Rs 809.15, down by 0.25 per cent on the BSE.
No comments:
Post a Comment